This link will take you to a non-ViiV Healthcare website. ViiV Healthcare does not recommend, endorse or accept liability for sites controlled by third-parties.

Careers

Facebook
Twitter
Instagram
LinkedIn
YouTube

United States

About us +
About us

We are ViiV Healthcare: 100% dedicated to HIV medicines and research and completely focused on people affected by HIV and AIDS.
Learn more about us

Our history & mission

Our commitment to inclusion & diversity

Our leadership

Corporate ethics and compliance

Contact our team
Our HIV medicines +
Our HIV medicines
Learn about our HIV medicines

Our medicines
HIV research +
HIV research

We are dedicated to treat, prevent and hopefully one day, cure HIV. Find out about our research initiatives in the fight against HIV.
Learn about our HIV research

Medicines in development

Implementation science research

Our stories of science and innovation
Community engagement +
Community engagement

We work actively with communities affected by HIV and AIDS around the world. Read about our community engagement initiatives.
Learn about our community engagement

Positive Action

accelerate Initiative

Positive Action AMP Grant

Community connections
Ending HIV +
Ending HIV

We are the only pharmaceutical company solely focused on curing HIV and AIDS, but of course, none of what we do can be achieved alone – we believe in the power of partnership.
Learn about ending HIV

HIV stigma

HIV Prevention

Policy Papers

Our stories of support for the HIV community

Our Culture Initiatives
We’re Here
News & Events +
News & Events

Our Media centre contains a range of resources including our latest and archived press releases and news updates, conferences and events we attend, our image and video library and social media information.
Press Releases

News

Conference and Events

Images and Video Gallery

Press Kits

Careers

Facebook
Twitter
Instagram
LinkedIn
YouTube

OPEN

About us +
About us

We are ViiV Healthcare: 100% dedicated to HIV medicines and research and completely focused on people affected by HIV and AIDS.
Learn more about us

Our history & mission

Our commitment to inclusion & diversity

Our leadership

Corporate ethics and compliance

Contact our team
Our HIV medicines +
Our HIV medicines
Learn about our HIV medicines

Our medicines
HIV research +
HIV research

We are dedicated to treat, prevent and hopefully one day, cure HIV. Find out about our research initiatives in the fight against HIV.
Learn about our HIV research

Medicines in development

Implementation science research

Our stories of science and innovation
Community engagement +
Community engagement

We work actively with communities affected by HIV and AIDS around the world. Read about our community engagement initiatives.
Learn about our community engagement

Positive Action

accelerate Initiative

Positive Action AMP Grant

Community connections
Ending HIV +
Ending HIV

We are the only pharmaceutical company solely focused on curing HIV and AIDS, but of course, none of what we do can be achieved alone – we believe in the power of partnership.
Learn about ending HIV

HIV stigma

HIV Prevention

Policy Papers

Our stories of support for the HIV community

Our Culture Initiatives
We’re Here
News & Events +
News & Events

Our Media centre contains a range of resources including our latest and archived press releases and news updates, conferences and events we attend, our image and video library and social media information.
Press Releases

News

Conference and Events

Images and Video Gallery

Press Kits

Careers

Facebook
Twitter
Instagram
LinkedIn
YouTube

OUR PRESS RELEASES & COMPANY STATEMENTS

Press releases
Company statements

These press releases and company statements are intended for journalists and analysts/investors

- All
- 2016
- 2017
- 2018
- 2019
- 2020
- 2021
- 2022
- 2023
- 2024

Showing results for

ViiV Healthcare announces U.S. FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV

08 Apr 2024
ViiV Healthcare announces interim data at CROI indicating superior efficacy of long-acting injectable HIV treatment Cabenuva (cabotegravir + rilpivirine) compared to daily oral therapy in individuals living with HIV who have adherence challenges

06 Mar 2024
ViiV Healthcare and The American Academy of HIV Medicine Announce Fellowship to Improve HIV Prevention in Key Communities

05 Mar 2024
ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses

04 Mar 2024
ViiV Healthcare to present data for its next generation of ultra long-acting treatments for HIV

28 Feb 2024
LATITUDE phase III interim trial data indicates ViiV Healthcare’s long-acting injectable HIV treatment Cabenuva (cabotegravir + rilpivirine) has superior efficacy compared to daily therapy in individuals living with HIV who have adherence challenges

21 Feb 2024
ViiV Healthcare announces new packaging option now available in the U.S. for Dovato (dolutegravir/lamivudine)

05 Feb 2024
ViiV Healthcare announces positive data demonstrating long-acting injectable Cabenuva (cabotegravir, rilpivirine) is as effective as daily oral Biktarvy (BIC/FTC/TAF) for the treatment of HIV-1

23 Feb 2023
Major Corporations Launch New Coalition to Help End HIV in the United States

01 Dec 2022
Importantes corporaciones crean nueva coalición para ayudar a acabar con el VIH en Estados Unidos

01 Dec 2022
ViiV Healthcare presents positive proof-of-concept findings for N6LS, an investigational, broadly neutralising antibody (bNAb) offering a potential new approach for the treatment of HIV

25 Oct 2022
ViiV Healthcare presents positive data showing Vocabria (cabotegravir) and Rekambys (rilpivirine) can be successfully implemented across a range of European healthcare settings

24 Oct 2022
ViiV Healthcare to showcase innovative HIV treatment and prevention portfolio at IDWeekᵀᴹ and HIV Glasgow

12 Oct 2022
ViiV Healthcare Announces Recipients of Largest Philanthropic Fund in the Us Dedicated to HIV Prevention for Black Women

07 Oct 2022
ViiV Healthcare announces support for community-based organizations with new Monkeypox Emergency Response Fund in the US

10 Aug 2022
ViiV Healthcare presents positive five-year data at AIDS 2022, demonstrating the durability of fostemsavir in people living with HIV who are heavily treatment-experienced

29 Jul 2022
ViiV Healthcare announces new data at AIDS 2022 from unblinded phase of HPTN 084 study in women in sub Saharan Africa showing continued superior efficacy of injectable cabotegravir long-acting for PrEP over daily, oral TDF/FTC tablets

28 Jul 2022
AVAC, BMGF, CIFF, MedAccess, Unitaid and ViiV Healthcare announce collaboration to catalyse more affordable access to long-acting cabotegravir for HIV prevention

28 Jul 2022
ViiV Healthcare and the Medicines Patent Pool sign new voluntary licensing agreement to expand access to innovative long-acting HIV prevention medicine

28 Jul 2022
ViiV Healthcare to present new data from innovative HIV treatment and prevention portfolio at AIDS 2022

25 Jul 2022
ViiV Healthcare commits to grant voluntary licence for patents relating to cabotegravir long-acting for prep to medicines patent pool

27 May 2022
ViiV Healthcare ranked #1 for the ninth successive year in PatientView’s ‘Corporate Reputation of Pharma – from the Patient Perspective 2021 - 2022’ survey results

26 Apr 2022
ViiV Healthcare announces US FDA approval of Triumeq PD, the first dispersible single tablet regimen containing dolutegravir, a once-daily treatment for children living with HIV

30 Mar 2022
ViiV Healthcare announces US FDA approval of Cabenuva (cabotegravir, rilpivirine) for virologically suppressed adolescents living with HIV who are 12 years of age or older and weigh at least 35 kg

29 Mar 2022
ViiV Healthcare announces label update for its long-acting HIV treatment, Cabenuva (cabotegravir, rilpivirine), to be initiated with or without an oral lead-in period

24 Mar 2022
ViiV Healthcare to present new long-term findings from its innovative 2-drug and long-acting HIV medicines portfolio at CROI 2022

07 Feb 2022
GSK announces settlement between ViiV Healthcare and Gilead Sciences, Inc. resolving litigation relating to Biktarvy and ViiV’s dolutegravir patents and entry into a patent licence agreement

01 Feb 2022
ViiV Healthcare announces US FDA approval of Cabenuva (cabotegravir, rilpivirine) for use every two months, expanding the label of the first and only complete long-acting HIV treatment

01 Feb 2022
ViiV Healthcare announces US FDA approval of Apretude (cabotegravir extended-release injectable suspension), the first and only long-acting injectable option for HIV prevention

21 Dec 2021
Less talk more action new report sponsored by ViiV Healthcare provides roadmap to achieve health equity by 2040

20 Oct 2021
ViiV Healthcare submits FDA application for first dispersible single tablet regimen containing dolutegravir (DTG) for children living with HIV

04 Oct 2021
ViiV Healthcare presents three-year switch data for Dovato (dolutegravir/lamivudine) confirming long-term, non-inferior efficacy with no virologic failure versus continuation of TAF-based regimens of at least three drugs

29 Sep 2021
FDA grants Priority Review to ViiV Healthcare’s New Drug Application for cabotegravir long-acting for prevention of HIV

28 Sep 2021
ViiV Healthcare announces exclusive license agreement with Shionogi to develop third-generation HIV integrase inhibitor with potential for ultra long-acting dosing intervals

28 Sep 2021
ViiV Healthcare to present key data that provides further support for the use of 2-drug regimens, including long-term efficacy, alongside new insights into living with HIV at IDWeek 2021

22 Sep 2021
ViiV Healthcare announces FDA Priority Review designation for cabotegravir long-acting for prevention of HIV

21 Sep 2021
ViiV Healthcare presents data from second Dovato (dolutegravir/lamivudine) switch study confirming non-inferior efficacy and no virologic failure versus a broad range of regimens of at least 3 drugs

17 Jul 2021
ViiV Healthcare study shows new long-acting HIV regimen Cabenuva (cabotegravir/rilpivirine) can be successfully implemented in broad range of US healthcare practices, even during COVID-19

17 Jul 2021
ViiV Healthcare to present new data from diverse portfolio and pipeline of 2-drug and long-acting regimens for HIV treatment and prevention at IAS 2021

17 Jul 2021
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of “ultra-long-acting” medicines for HIV

22 Jun 2021
ViiV Healthcare initiates rolling submission of new drug application with US FDA for long-acting cabotegravir for prevention of HIV

04 May 2021
ViiV Healthcare presents positive proof-of-concept findings for GSK3640254, a novel, investigational maturation inhibitor for the treatment of HIV

09 Mar 2021
ViiV Healthcare presents data for long-acting cabotegravir and rilpivirine for the treatment of HIV showing continued virologic suppression to 96 weeks

06 Mar 2021
ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside pipeline advances at CROI 2021

02 Mar 2021
ViiV Healthcare Builds on accelerate Initiative, Extending Community-Centered Approach Nationally to Disrupt Disparities in Care for Black Same-Gender-Loving Men Living With HIV

25 Feb 2021
ViiV Healthcare Submits Supplemental New Drug Application to US FDA for Expanded Use of Cabenuva (cabotegravir, rilpivirine) as an HIV Treatment for Use Every 2-Months

24 Feb 2021
ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment

21 Jan 2021
ViiV Healthcare announces results of the PROgress study demonstrating that the inclusion of patient reported outcomes into clinical practice can improve HIV care

18 Nov 2020
ViiV Healthcare receives FDA Breakthrough Therapy Designation for investigational, long-acting cabotegravir for HIV prevention

17 Nov 2020
ViiV Healthcare announces investigational injectable cabotegravir is superior to oral standard of care for HIV prevention in women

09 Nov 2020
ViiV Healthcare presents positive new findings from two studies of its investigational, long-acting regimen of cabotegravir and rilpivirine, including five-year data showing long-term durability, efficacy, safety, and tolerability

22 Oct 2020
ViiV Healthcare presents continued positive findings from first-ever implementation science study on integrating an investigational once-monthly injectable HIV treatment into US healthcare practices

22 Oct 2020
ViiV Healthcare announces analysis showing no antiretroviral therapy interruptions due to COVID-19 across its clinical development programme for investigational, long-acting cabotegravir and rilpivirine

21 Oct 2020
ViiV Healthcare presents long-term switch data for Dovato demonstrating non-inferior efficacy in adults with HIV-1 and zero cases of virologic failure versus TAF-containing regimens

08 Oct 2020
ViiV Healthcare announces dolutegravir plus lamivudine three-year data confirming long-term viral suppression non-inferior to a 3-drug regimen for treatment-naïve adults with HIV-1

05 Oct 2020
ViiV Healthcare presents a new podcast about the Power of Being Seen

01 Oct 2020
ViiV Healthcare announces start of implementation science study to identify and evaluate approaches to integrating its investigational, every-two-month, injectable HIV treatment in European healthcare practices

28 Sep 2020
ViiV Healthcare to present long-term safety and efficacy data for 2-drug regimen Dovato (dolutegravir/lamivudine) alongside other key research advances at the HIV Glasgow 2020 congress

28 Sep 2020
ViiV Healthcare anuncia la publicación de su informe de investigación “Tal Como Soy”, que analiza las fuerzas socioeconómicas que afectan el acceso a servicios de salud de VIH para hombres latinxs gay y bisexuales

15 Sep 2020
ViiV Healthcare Announces New Research Report “Here as I Am,” on Socio-Economic Forces Affecting Access to HIV Care for Latinx Gay and Bisexual Men

15 Sep 2020
ViiV Healthcare announces data demonstrating the feasibility of Dovato (dolutegravir/lamivudine) as a treatment option for rapid initiation after diagnosis in adults with HIV-1

20 Aug 2020
ViiV Healthcare announces FDA approval of an expanded indication for Dovato (dolutegravir/lamivudine), a complete two-drug regimen for virologically suppressed adults with HIV-1

06 Aug 2020
ViiV Healthcare announces superior efficacy of investigational, long-acting injectable formulation of cabotegravir dosed every two months over daily oral PrEP

07 Jul 2020
ViiV Healthcare shares new data from Positive Perspectives, Wave 2 study, confirming a more holistic approach to HIV care can improve quality of life

04 Jul 2020
ViiV Healthcare presents positive data from first-ever implementation research study on how best to integrate a investigational once-monthly injectable HIV treatment in US healthcare practices

04 Jul 2020
ViiV Healthcare announces US FDA approval for Rukobia (fostemsavir), a first-in-class treatment for HIV in adults with few treatment options available

02 Jul 2020
ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside extensive insights into the evolving needs of people living with HIV at 23rd International AIDS Conference (AIDS 2020: Virtual)

02 Jul 2020
ViiV Healthcare announces grantees selected as part of £3 million Fund dedicated to HIV research and community-based programmes during COVID-19 pandemic

30 Jun 2020
ViiV Healthcare announces US FDA approval of the first-ever dispersible tablet formulation of dolutegravir, Tivicay PD, a once-daily treatment for children living with HIV

12 Jun 2020
National AIDS Memorial and ViiV Healthcare Create Mary Bowman Arts in Activism Award to Support Young Artist-Activists Committed to the Fight Against HIV/AIDS

26 May 2020
Global HIV prevention study to stop early after ViiV Healthcare’s long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP

18 May 2020
ViiV Healthcare announces £3 million global fund to research the impact of COVID-19 on the HIV community and fill gaps in prevention, treatment and care during the pandemic

27 Apr 2020
ViiV Healthcare presents positive, 48-week data from phase III study showing every-two-month regimen of investigational long-acting, injectable cabotegravir and rilpivirine has similar efficacy to once-monthly dosing

09 Mar 2020
ViiV Healthcare presents positive long-term data from phase III study demonstrating efficacy and safety of cabotegravir and rilpivirine, its investigational, long-acting HIV-treatment regimen in adults living with HIV-1

09 Mar 2020
ViiV Healthcare receives complete response letter from US FDA for use of investigational cabotegravir and rilpivirine long-acting regimen in the treatment of HIV

21 Dec 2019
ViiV Healthcare files submissions to the FDA and EMA for the first-ever dispersible formulation of dolutegravir (DTG) for children living with HIV

13 Dec 2019
ViiV Healthcare submits New Drug Application to the FDA for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available

05 Dec 2019
ViiV Healthcare announces exclusive licensing agreement with the National Institutes of Health for investigational “bNAb” with potential for long-acting HIV treatment and prevention

21 Nov 2019
EACS 2019: ViiV Healthcare to present 17 abstracts from its portfolio, addressing the diverse needs of people living with HIV

06 Nov 2019
ViiV Healthcare Submits Supplemental New Drug Application to US FDA for Use of Dovato in Virologically-Suppressed Adults with HIV-1

16 Oct 2019
IDWeek 2019: ViiV Healthcare to present 20 abstracts from its innovative R&D portfolio with focus on 2-drug and long-acting regimens and mental health impact of HIV

02 Oct 2019
ViiV Healthcare reports positive phase III study results of investigational, long-acting, injectable HIV-treatment regimen administered every two months

22 Aug 2019
ViiV Healthcare submits regulatory application to European Medicines Agency for investigational cabotegravir to be used in combination with rilpivirine as the first monthly injectable treatment for HIV

29 Jul 2019
ViiV Healthcare presents GEMINI 1 & 2 studies through Week 96 showing 2-drug regimen of dolutegravir plus lamivudine continues to demonstrate high efficacy rates and no cases of treatment emergent resistance

24 Jul 2019
ViiV Healthcare announces positive Week 48 results in first study to evaluate treatment switch from TAF-containing regimen with three or more drugs to 2-drug regimen of dolutegravir/lamivudine for HIV-1 infection

24 Jul 2019
ViiV Healthcare presents positive 96-week data from phase III study of investigational fostemsavir in heavily treatment-experienced patients with HIV at IAS 2019

22 Jul 2019
IAS 2019: ViiV Healthcare showcasing innovation in HIV science

15 Jul 2019
ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with a 2-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switching from a TAF-containing, 3-drug regimen

10 Jul 2019
ViiV Healthcare announces start of first-ever study to identify and evaluate approaches to implementing its once-monthly injectable HIV treatment in clinical practice

08 Jul 2019
ViiV Healthcare submits New Drug Application to US FDA for the first monthly, injectable, two-drug regimen of cabotegravir and rilpivirine for treatment of HIV

30 Apr 2019
US FDA approves ViiV Healthcare’s Dovato (dolutegravir/lamivudine), the first, once-daily, single-tablet, two-drug regimen for treatment-naïve HIV-1 adults

09 Apr 2019
ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir in heavily treatment-experienced patients with HIV

31 Oct 2018
ViiV Healthcare reports positive 48-week results for second phase III study for novel, long-acting, injectable HIV-treatment regimen

30 Oct 2018
ViiV Healthcare presents three-year data for investigational long-acting injectable, two-drug HIV regimen

29 Oct 2018
ViiV Healthcare reports positive 48-week results for first pivotal, phase III study for novel, long-acting, injectable HIV-treatment regimen

15 Aug 2018
ViiV Healthcare announces SWORD 100-week data for Juluca (dolutegravir/rilpivirine) at AIDS 2018

24 Jul 2018
ViiV Healthcare presents phase III data showing two drug regimen has similar efficacy to a three-drug regimen in treatment naïve HIV patients, with no resistance

24 Jul 2018
ViiV Healthcare shares data from landmark 2-drug regimen trials at AIDS 2018

18 Jul 2018
ViiV Healthcare announces positive new dolutegravir data for the treatment of people living with HIV co-infected with tuberculosis

05 Mar 2018
ViiV Healthcare files patent infringement litigation against Gilead Sciences Inc. over bictegravir

08 Feb 2018
ViiV Healthcare launches eighth phase III study in two- drug regimen programme for HIV-1 treatment

08 Feb 2018
ViiV Healthcare announces start of phase III study of long-acting cabotegravir for HIV prevention in women

30 Nov 2017
ViiV Healthcare starts third phase III HIV treatment study investigating long-acting two-drug regimen of cabotegravir plus rilpivirine

27 Nov 2017
ViiV Healthcare announces US FDA approval for Juluca®

21 Nov 2017
ViiV Healthcare announces positive phase III results from the BRIGHTE study of fostemsavir in heavily treatment-experienced patients with HIV

27 Oct 2017
New results from the Positive Perspectives global survey provide insights into the attitudes and perceptions of people living with HIV

25 Oct 2017
ViiV Healthcare Awards $1 Million In Grants For Positive Action For Women In The U.S.

05 Sep 2017
ViiV Healthcare Expands U.S. Commitment to Youth Living With HIV Through Its Positive Action Program

10 Aug 2017
ViiV Healthcare and NEAT-ID announce results from the NEAT 022 study at the International AIDS Society meeting in Paris

25 Jul 2017
ViiV Healthcare announces superior efficacy of dolutegravir versus lopinavir/ritonavir in second-line HIV treatment in resource-limited settings

25 Jul 2017
Phase II study results showed comparable viral suppression rates at 96 weeks for a two-drug regimen

24 Jul 2017
ViiV Healthcare shares data from its innovative portfolio with HIV community at IAS 2017

20 Jul 2017
ViiV Healthcare submits regulatory applications for the first HIV maintenance regimen comprising only two medicines

01 Jun 2017
ViiV Healthcare Announces FDA Approval of SELZENTRY® (maraviroc) for Use in Children and Adolescents Living With HIV

04 Nov 2016
ViiV Healthcare extends Medicines Patent Pool license agreement for dolutegravir to cover all lower middle-income countries

25 Apr 2016
ViiV Healthcare announces first phase II HIV prevention study results for investigational long-acting injectable cabotegravir

24 Feb 2016
ViiV Healthcare announces phase II study results for first two drug, long-acting injectable regimen for HIV-1 treatment

23 Feb 2016
ViiV Healthcare to progress collaboration with Janssen to develop the first long-acting, two drug injectable regimen for treatment of HIV

07 Jan 2016
April
march
February
February
April
January
2022
October
August
July
March
2018
November
October
September
August
July
June
2017
November
April
February
2016
January
October
June
September
July
March
May
February
January
November
2021
August
October
September
June
July
January
April
2020
March
May
November
December
October
August
July
April
2019

These press releases and company statements are intended for journalists and analysts/investors

Voluntary wholesaler/distributor and retail-level recall in the US of one lot of Tivicay (dolutegravir) 50 mg Tablets due to incorrect expiry date

23 May 2022
ViiV Healthcare is working with Medicines Patent Pool to progress voluntary licensing for cabotegravir long-acting for PrEP

04 Apr 2022
ViiV Healthcare presents real-world evidence at EACS 2021 reinforcing the use of its 2-drug regimens Dovato (dolutegravir/lamivudine) and Juluca▼ (dolutegravir/rilpivirine) for the treatment of people living with HIV

28 Oct 2021
ViiV Healthcare COVID-19 Community Emergency Response Fund

27 Apr 2020
ViiV Healthcare ranks #1 company in the PatientView ‘Corporate Reputation of Pharma – from the Patient Perspective 2019 – 2020’ survey

21 Apr 2020
ViiV Healthcare’s commitment to support AIDS2020 and key conferences during COVID-19 outbreak

30 Mar 2020
COVID-19 Guidance to Investigators

27 Mar 2020
Our Response to COVID-19

16 Mar 2020
April
March
2020

Media contacts

Media contact details for our global headquarters and United States. For press contacts in our local operating companies, please visit our country websites.

In you have a media query, please use our Contact our team form here.

Global Press Office

Rachel Jaikaran
Head of Global Communications ViiV Healthcare
Tel: +44 (0) 78 2352 3755

US Press Office

Audrey Abernathy
Head of US Communications & External Affairs
Tel: +1 919 605 4521

Connect with us

ViiV Healthcare

410 Blackwell Street
Durham
North Carolina USA
27701

Tel: +1 877 ViiVUSA (+1 877 844 8872)

Terms of use
Cookie policy
Privacy notice
Sitemap
All our locations

Report an adverse event

To report a suspected side effect, please use our online reporting form.

Your Privacy Choices

YOU ARE LEAVING THE SITE

You are about to leave a ViiV Healthcare website. By clicking this link, you will be taken to a website that is independent from ViiV Healthcare. The site you are linking to is not controlled or endorsed by ViiV Healthcare and ViiV Healthcare is not responsible for the content provided on that site.

Cancel Accept

Select Country & Language

Global

English

Australia

English
Canada

English Français
España

Español
France

Français
Germany

Deutsche
Italy

Italiano
Japan

日本人
Netherlands

Nederlands
Switzerland

English Français Deutsch
United States

English

You are accessing historic archive material

This is an archived press release which may not reflect current medical knowledge and should not be used as a source of information on the present label, safety data or efficacy data for ViiV Healthcare products and/or their uses. Please refer to your nationally approved label or summary of product characteristics for up-to-date product information.

I understand